Source:http://linkedlifedata.com/resource/pubmed/id/16827861
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2006-7-10
|
| pubmed:abstractText |
Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described. To investigate the risk of LAR (rejection > or = 6 months post-transplantation) data from the Scientific Registry of Transplant Recipients (SRTR) were used. We studied adult primary liver transplant recipients transplanted between June 1, 1995, and April 30, 2004, with hepatitis C virus (HCV) (n = 3356), hepatitis B virus (HBV) (n = 550) or a nonviral (n = 5740) primary cause of liver disease who were recorded as receiving continuous 3-(MMF + Tacro + steroids) versus 2-drug (Tacro + steroids) therapy for at least 6 months immediately post transplantation. Kaplan-Meier analysis showed significantly lower LAR rates 4 years post-transplant in 3- versus 2-drug HCV, HBV and nonviral disease patients. Multivariate regression confirmed 3- versus 2-drug therapy to be associated with a decreased risk of LAR. Late graft survival was significantly lower at 4 years post-transplant for patients with LAR 6-12 months post-transplantation versus patients with early rejection (78.0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1600-6135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1609-16
|
| pubmed:dateRevised |
2007-2-14
|
| pubmed:meshHeading |
pubmed-meshheading:16827861-Acute Disease,
pubmed-meshheading:16827861-Adolescent,
pubmed-meshheading:16827861-Adult,
pubmed-meshheading:16827861-Aged,
pubmed-meshheading:16827861-Female,
pubmed-meshheading:16827861-Follow-Up Studies,
pubmed-meshheading:16827861-Graft Rejection,
pubmed-meshheading:16827861-Hepacivirus,
pubmed-meshheading:16827861-Hepatitis B,
pubmed-meshheading:16827861-Hepatitis B virus,
pubmed-meshheading:16827861-Hepatitis C,
pubmed-meshheading:16827861-Humans,
pubmed-meshheading:16827861-Liver Transplantation,
pubmed-meshheading:16827861-Male,
pubmed-meshheading:16827861-Middle Aged,
pubmed-meshheading:16827861-Mycophenolic Acid,
pubmed-meshheading:16827861-Risk Factors,
pubmed-meshheading:16827861-Time Factors
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients.
|
| pubmed:affiliation |
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. rwiesner@mayo.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|